General description
Hydroxyurea (also known as hydroxycarbamide) is used in the management of sickle cell disease, and in treatment protocols for chronic myeloproliferative disorders.
INN
Hydroxycarbamide
ATC codes
Medicine type
Chemical agent
EML status history
First added in 2009
(TRS
958)
for
Chronic myeloid leukaemia, not elsewhere classified
Added in 2009
(TRS
958)
for
Squamous cell carcinoma of oropharynx
Added in 2011
(TRS
965)
for
Other specified sickle cell disorders or other haemoglobinopathies
Removed in 2015
(TRS
994)
for
Squamous cell carcinoma of oropharynx
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Section
Other medicines for haemoglobinopathies
- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg